Discover
MIRM
Mirum Pharmaceuticals, Inc.
91.83
2 x 76.76
2 x 134.63
bid
ask
-
6.99
7.07%
2 @ 04:00 AM
91.83 +0.00 (0.00%)
| Ytd | 16.26% | |
| 1y | 21.92% |
91.73
day range
98.76
63.23
52 week range
130.00
| Open | 98.76 | Prev Close | 98.82 | Low | 91.73 | High | 98.76 | Mkt Cap | 5.96B |
| Vol | 1.80M | Avg Vol | 760.35K | EPS | -14.08 | P/E | N/A | Forward P/E | -264.89 |
| Beta | 0.49 | Short Ratio | 9.09 | Inst. Own | 111.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 104.24 | 200-d Avg | 97.22 | 1yr Est | 138.21 |
MIRM News
seekingalpha.com
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conferen
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conferen
seekingalpha.com
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events
Mirum Pharmaceuticals is approaching major catalysts, notably the FDA's PDUFA decision for zilurgise
businesswire.com
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq L
benzinga.com
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market O